Can insulin resistance persist even when fasting glucose improves?

Early-stage metabolic dysfunction is frequently masked by compensatory pancreatic hyperinsulinemia, meaning that normal or clinically improved fasting glucose levels do not rule out severe underlying insulin resistance.

Mechanistic drivers of persistent resistance

• Visceral adiposity and inflammation: Visceral fat drains excess free fatty acids directly into the portal vein and secretes pro-inflammatory cytokines. This chronic inflammatory state impairs key downstream signaling intermediates, specifically insulin receptor substrate-1 (IRS-1), preserving peripheral resistance even when glucose markers improve.
• Circadian and sleep disruption: Sleep restriction and disorders like obstructive sleep apnea elevate insulin resistance (HOMA-IR) independently of obesity. This is driven by intermittent hypoxia and oxidative stress, which trigger elevated lipolysis and systemic inflammation.
• Genetic and nutrient signaling limits: Genetic variations in downstream signaling pathways cap the body’s compensatory capacity. Concurrently, deficiencies in key nutrients such as magnesium and vitamin D disrupt insulin receptor kinase activity and cellular glucose transport.
• Beta-cell vulnerability: While pancreatic beta cells initially scale up insulin secretion to maintain normal blood glucose, vulnerable beta cells cannot sustain this high output. This limits compensatory capacity and accelerates systemic metabolic decline.

Bottom line

• Normal fasting glucose can mask severe, persistent insulin resistance, which is maintained by a synergistic network of visceral adiposity, circadian disruption, genetic signaling limits, and nutrient deficiencies that bypass homeostatic glucose controls.